Non-Small Cell Lung Cancer Pipeline
Non-Small Cell Lung Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme LLC, Qilu Pharma, Merus N.V., Zymeworks BC, NeoImmune Tech